A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Kittichai Promrat, Glen Lutchman, Gabriel I. Uwaifo, Renee J. Freedman, Alejandro Soza, Theo Heller, Edward Doo, Marc Ghany, Ahalya Premkumar, Yoon Park, T. Jake Liang, Jack A. Yanovski, David E. Kleiner, Jay H. Hoofnagle – 5 January 2004 – Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance plays a central role.